Search
Patexia Research
Case number 3:18-cv-00274

Celltrion, Inc. et al v. Genentech, Inc. et al > Summary

Court Case Number 3:18-cv-00274

Filing Date Jan 11, 2018

Termination Date Jun 11, 2018

Court California Northern District Court

Status Judgment - Other

JudgesJeffrey S. White

Plaintiff Attorneys

33

Celltrion
Attorney Name: Elaine H. Blais
Goodwin Procter LLP

TEVA PHARMACEUTICALS INTERNATIONAL GmbH
Attorney Name: Elaine H. Blais
Goodwin Procter LLP

Teva Pharmaceuticals
Attorney Name: Elaine H. Blais
Goodwin Procter LLP

Celltrion Healthcare Co., Ltd.
Attorney Name: Robert Cerwinski
Goodwin Procter LLP

Celltrion
Attorney Name: Robert Cerwinski
Goodwin Procter LLP

TEVA PHARMACEUTICALS INTERNATIONAL GmbH
Attorney Name: Robert Cerwinski
Goodwin Procter LLP

Teva Pharmaceuticals
Attorney Name: Robert Cerwinski
Goodwin Procter LLP

Celltrion Healthcare Co., Ltd.
Attorney Name: Neel Chatterjee
Goodwin Procter LLP

Celltrion
Attorney Name: Neel Chatterjee
Goodwin Procter LLP

TEVA PHARMACEUTICALS INTERNATIONAL GmbH
Attorney Name: Neel Chatterjee
Goodwin Procter LLP

Teva Pharmaceuticals
Attorney Name: Neel Chatterjee
Goodwin Procter LLP

Celltrion Healthcare Co., Ltd.
Attorney Name: Kevin J. Dejong
Goodwin Procter LLP

Celltrion
Attorney Name: Kevin J. Dejong
Goodwin Procter LLP

TEVA PHARMACEUTICALS INTERNATIONAL GmbH
Attorney Name: Kevin J. Dejong
Goodwin Procter LLP

Teva Pharmaceuticals
Attorney Name: Kevin J. Dejong
Goodwin Procter LLP

Celltrion Healthcare Co., Ltd.
Attorney Name: Cynthia Lambert Hardman
Goodwin Procter LLP

Celltrion
Attorney Name: Cynthia Lambert Hardman
Goodwin Procter LLP

TEVA PHARMACEUTICALS INTERNATIONAL GmbH
Attorney Name: Cynthia Lambert Hardman
Goodwin Procter LLP

Teva Pharmaceuticals
Attorney Name: Cynthia Lambert Hardman
Goodwin Procter LLP

Celltrion Healthcare Co., Ltd.
Attorney Name: Elizabeth J. Holland
Goodwin Procter LLP

Celltrion
Attorney Name: Elizabeth J. Holland
Goodwin Procter LLP

TEVA PHARMACEUTICALS INTERNATIONAL GmbH
Attorney Name: Elizabeth J. Holland
Goodwin Procter LLP

Teva Pharmaceuticals
Attorney Name: Elizabeth J. Holland
Goodwin Procter LLP

Celltrion Healthcare Co., Ltd.
Attorney Name: Brett M. Schuman
Goodwin Procter LLP

Celltrion
Attorney Name: Brett M. Schuman
Goodwin Procter LLP

TEVA PHARMACEUTICALS INTERNATIONAL GmbH
Attorney Name: Brett M. Schuman
Goodwin Procter LLP

Teva Pharmaceuticals
Attorney Name: Brett M. Schuman
Goodwin Procter LLP

Celltrion Healthcare Co., Ltd.
Attorney Name: Daryl L. Wiesen
Goodwin Procter LLP

TEVA PHARMACEUTICALS INTERNATIONAL GmbH
Attorney Name: Daryl L. Wiesen
Goodwin Procter LLP

Celltrion
Attorney Name: Daryl L. Wiesen
Goodwin Procter LLP

Teva Pharmaceuticals
Attorney Name: Daryl L. Wiesen
Goodwin Procter LLP

Celltrion Healthcare Co., Ltd.
Attorney Name: Sehoon Kim
Celltrion Healthcare Co., Ltd.

Cause

28:1338 Patent Infringement

Related Patents

Doc No Title Issue date
09714293 Production of proteins in glutamine-free cell culture media Jul 25, 2017
09487809 Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase Nov 8, 2016
09428766 Protein expression from multiple nucleic acids Aug 30, 2016
09428548 Enhanced protein purification through a modified protein A elution Aug 30, 2016
09249218 Protein purification Feb 2, 2016
09080183 Promoter Jul 14, 2015
09047438 Chromatography equipment characterization Jun 2, 2015
08822655 Pre-filtration adjustment of buffer solutes Sep 2, 2014
08771988 Protein expression from multiple nucleic acids Jul 8, 2014
08691232 Extending time to disease progression or survival in cancer patients Apr 8, 2014
08633302 Variable tangential flow filtration Jan 21, 2014
08574869 Prevention of disulfide bond reduction during recombinant production of polypeptides Nov 5, 2013
08512983 Production of proteins in glutamine-free cell culture media Aug 20, 2013
08460895 Method for producing recombinant proteins with a constant content of pCO2 in the medium Jun 11, 2013
08440402 Gene detection assay for improving the likelihood of an effective response to a HER2 antibody cancer therapy May 14, 2013
08425908 Treatment with anti-ErbB2 antibodies Apr 23, 2013
08357301 Chromatography equipment characterization Jan 22, 2013
08076066 Gene detection assay for improving the likelihood of an effective response to a HER2 antibody cancer therapy Dec 13, 2011
07993834 Detection of ErbB2 gene amplification to increase the likelihood of the effectiveness of ErbB2 antibody breast cancer therapy Aug 9, 2011
07923221 Methods of making antibody heavy and light chains having specificity for a desired antigen Apr 12, 2011
07892549 Treatment with anti-ErbB2 antibodies Feb 22, 2011
07846441 Treatment with anti-ErbB2 antibodies Dec 7, 2010
07807799 Reducing protein A leaching during protein A affinity chromatography Oct 5, 2010
07501122 Treatment with anti-ErbB2 antibody combinations Mar 10, 2009
07485704 Reducing protein A leaching during protein A affinity chromatography Feb 3, 2009
07449184 Fixed dosing of HER antibodies Nov 11, 2008
07390660 Methods for growing mammalian cells in vitro Jun 24, 2008
07371379 Dosages for treatment with anti-ErbB2 antibodies May 13, 2008
06716602 Metabolic rate shifts in fermentations expressing recombinant proteins Apr 6, 2004
06627196 Dosages for treatment with anti-ErbB2 antibodies Sep 30, 2003
06620918 Separation of polypeptide monomers Sep 16, 2003
06610516 Cell culture process Aug 26, 2003
06586206 Methods for making recombinant proteins using apoptosis inhibitors Jul 1, 2003
06489447 Protein purification Dec 3, 2002
06417335 Protein purification Jul 9, 2002
06407213 Method for making humanized antibodies Jun 18, 2002
06339142 Protein purification Jan 15, 2002
06331415 Methods of producing immunoglobulins, vectors and transformed host cells for use therein Dec 18, 2001
05821337 Immunoglobulin variants Oct 13, 1998
05530101 Humanized immunoglobulins Jun 25, 1996
Menu